Leslie Anderson, MD
Family Medicine · Lonoke, ARNPI 1821050022
Payments from drug & device makers
Across 169 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$660
- Pfizer$272
- Abbott$232
- Lilly USA, LLC$142
- Boehringer Ingelheim$101
- Sumitomo Pharma America, Inc.$92
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,556100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $660 |
| Pfizer | 27 | $272 |
| Abbott | 13 | $232 |
| Lilly USA, LLC | 9 | $142 |
| Boehringer Ingelheim | 6 | $101 |
| Sumitomo Pharma America, Inc. | 7 | $92 |
| Kyowa Kirin, Inc. | 4 | $88 |
| GSK | 5 | $82 |
| Exact Sciences | 4 | $65 |
| G1 Therapeutics, Inc. | 1 | $63 |
| Johnson & Johnson | 4 | $60 |
| Merck | 4 | $54 |
| Eisai Inc. | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| Amgen | 3 | $41 |
| Novo Nordisk | 3 | $41 |
| AstraZeneca | 3 | $41 |
| Upsher-smith Laboratories LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Mylan Specialty L.p. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Viatris Specialty LLC | 1 | $19 |
| Optinose US, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,556 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 146 | $158,897 |
| JardianceEmpagliflozin | 148 | $129,512 |
| EliquisApixaban | 139 | $112,852 |
| MounjaroTirzepatide | 66 | $69,459 |
| XareltoRivaroxaban | 38 | $28,015 |
| MyrbetriqMirabegron | 47 | $26,993 |
| CreonLipase/Protease/Amylase | 24 | $23,564 |
| TrulicityDulaglutide | 19 | $17,909 |
| TrintellixVortioxetine Hydrobromide | 26 | $16,963 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $15,791 |
| FarxigaDapagliflozin Propanediol | 18 | $14,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $13,175 |
| LinzessLinaclotide | 17 | $11,099 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $8,624 |
| GemtesaVibegron | 18 | $8,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $41 | $158,897146 claims |
| Boehringer IngelheimJardiance | $101 | $129,512148 claims |
| PfizerEliquis | $272 | $112,852139 claims |
| Lilly USA, LLCMounjaro, Trulicity | $142 | $87,36885 claims |
| AbbVieCreon, Linzess, Synthroid | $660 | $39,502114 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $82 | $36,96864 claims |
| Johnson & JohnsonXarelto | $60 | $28,01538 claims |
| AstraZenecaFarxiga, Symbicort | $41 | $22,90348 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $35 | $16,96326 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $92 | $8,58418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Lonoke
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.